• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

IntelGenx

IntelGenx to reclaim global rights to oral thin-film migraine treatment

December 19, 2017 By Sarah Faulkner

IntelGenx

IntelGenx (CVE:IGX) is slated to regain exclusive global rights to develop and sell its Rizaport oral thin-film acute migraine treatment in January, according to a report from BioTuesdays. The company’s partner, RedHill Biopharma (NSDQ:RDHL), has decided to end its co-development and commercialization relationship with IntelGenx, the news site reported. “We were expecting RedHill’s decision because in recent […]

Filed Under: Drug-Device Combinations, Featured, Neurological, Pharmaceuticals, Research & Development, Wall Street Beat Tagged With: IntelGenx, redhillbiopharma

IntelGenx gets green light to launch Ph2 Alzheimer’s study in Canada

December 15, 2017 By Sarah Faulkner

IntelGenx

IntelGenx (CVE:IGX) said today that Health Canada approved its application to study its montelukast VersaFilm therapy in adults with mild to moderate Alzheimer’s disease. The Phase IIa proof-of-concept trial is slated to begin screening patients in the first quarter of next year. The 70-patient study is designed to evaluate the safety, feasibility, tolerability and efficacy […]

Filed Under: Clinical Trials, Featured, Neurological, Pharmaceuticals, Wall Street Beat Tagged With: IntelGenx

IntelGenx misses Q2 sales, earnings estimates

August 11, 2017 By Sarah Faulkner

IntelGenx

Drug delivery company IntelGenx (CVE:IGX) missed expectations on Wall Street yesterday with its second quarter results. The Quebec-based company posted a net loss of -$550,000 on sales of $1.1 million for the 3 months ended June 30, paring its losses by 32% on sales growth of 64% compared with the same period last year. Adjusted […]

Filed Under: Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: IntelGenx

IntelGenx, Endo Ventures ink development and commercialization deal

December 28, 2016 By Sarah Faulkner

IntelGenx

IntelGenx (OTCQX:IGXT) said today that it inked a development and commercialization deal with pharmaceutical company Endo Ventures. According to the agreement, the 2 companies will develop a new product using IntelGenx’s VersaFilm drug delivery technology to bring to the market in the U.S. Endo will have certain exclusive rights to market and sell the product in the […]

Filed Under: Featured, Pharmaceuticals, Research & Development, Wall Street Beat Tagged With: Endo Ventures Inc., IntelGenx

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS